Cell & Gene Therapy: Understanding & Overcoming Challenges in Pricing & Patient Access

Linda Pissott Reig, shareholder and co-chair of the firm's FDA practice, served as a presenter during BioNJ's Legal, Compliance & Regulatory Forum. The session entitled, “Cell & Gene Therapy: Understanding & Overcoming Challenges in Pricing & Patient Access” took an in-depth look at the trajectory of cell and gene therapies in the U.S. market and examined successes, failures and opportunities within the industry.

In addition to contributing to the presentation, Linda also helped select the esteemed panel which included:

• Leigh Anne Leas, Vice President & North America Head, Public Policy, Novartis
• Michael Sherman, M.D., Executive Vice President & Chief Medical Officer, Harvard Pilgrim Healthcare & Tufts Health Plan; Department of Population Medicine, Harvard Medical School
• Mark Trusheim MSc, Strategic Director, NEWDIGS, Visiting Scientist, Sloan School of Management Massachusetts Institute of Technology and President, Co-Bio Consulting
• Mark Gaydos, Vice President & Head, North America, General Medicines & Established Products & U.S. Advertising & Promotion, Sanofi